Overview
- In the TRIUMPH-4 study, 445 adults with overweight or obesity and knee osteoarthritis were randomized 1:1:1 to retatrutide 9 mg, retatrutide 12 mg or placebo for 68 weeks.
- On an on‑treatment analysis, average weight loss reached 26.4% with 9 mg and 28.7% with 12 mg versus 2.1% with placebo; including discontinuations, losses were 20.0% and 23.7% versus 4.6%.
- Knee pain improved meaningfully, with WOMAC pain scores falling about 4.4–4.5 points on retatrutide versus 2.4 on placebo, and roughly two‑thirds to three‑quarters achieving a 70% pain reduction.
- A high share achieved deep weight‑loss thresholds, including 58.6% reaching at least 25% loss and 39.4% reaching at least 30% on 12 mg, while 12.2% (9 mg) and 18.2% (12 mg) discontinued due to adverse events vs 4% on placebo.
- Common side effects included nausea, diarrhea, constipation and vomiting; dysesthesia occurred in 8.8% (9 mg) and 20.9% (12 mg), cardiometabolic markers improved, and systolic blood pressure fell by 14 mm Hg at 12 mg; full data and peer‑reviewed publication are pending.